PULMONARY ARTERIAL HYPERTENSION (PAH)
Clinical trials for PULMONARY ARTERIAL HYPERTENSION (PAH) explained in plain language.
Never miss a new study
Get alerted when new PULMONARY ARTERIAL HYPERTENSION (PAH) trials appear
Sign up with your email to follow new studies for PULMONARY ARTERIAL HYPERTENSION (PAH), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill hopes to ease breathing in rare lung conditions
Disease control Recruiting nowThis study tests an experimental oral drug called ROC-101 in 40 adults with pulmonary arterial hypertension (PAH) or pulmonary hypertension linked to interstitial lung disease (ILD-PH). Participants take the drug alongside their standard care for 24 weeks, with a long-term follow…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION (PAH)
Phase: PHASE2 • Sponsor: AllRock Bio, Inc. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New antibody drug aims to ease lung blood pressure
Disease control Recruiting nowThis study tests an experimental drug called REGN13335 in 99 adults with pulmonary arterial hypertension (PAH), a condition where high blood pressure in the lungs makes the heart work harder. Participants will receive either the drug or a placebo, on top of their usual PAH medica…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION (PAH)
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Which PAH treatment strategy works better: adding a third drug or increasing the dose?
Disease control Recruiting nowThis study compares two ways to intensify treatment for people with pulmonary arterial hypertension (PAH) who are not doing well enough on standard dual therapy. One group adds a third type of medication (a prostacyclin pathway agent), while the other group increases the dose of …
Matched conditions: PULMONARY ARTERIAL HYPERTENSION (PAH)
Phase: PHASE4 • Sponsor: University of Sao Paulo General Hospital • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New injection shows promise for Hard-to-Treat lung condition
Disease control Recruiting nowThis study tests an investigational drug called IMC-003 in 120 adults with pulmonary arterial hypertension (PAH), a serious lung condition that makes the heart work harder. Participants receive multiple injections of the drug or a placebo, alongside their usual treatments. The go…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION (PAH)
Phase: PHASE1, PHASE2 • Sponsor: ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New antibody drug ZMA001 enters first human safety trial
Disease control Recruiting nowThis phase 1 trial tests the safety of a new drug called ZMA001 in 96 healthy adults. ZMA001 is a monoclonal antibody designed to reduce lung damage in pulmonary arterial hypertension (PAH), a serious condition. Participants receive a single dose of the drug or placebo and are mo…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION (PAH)
Phase: PHASE1 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Two-Drug combo may boost outcomes for High-Risk PAH patients
Disease control Recruiting nowThis study compares starting with two oral medications (tadalafil and ambrisentan) versus one medication alone in people newly diagnosed with pulmonary arterial hypertension (PAH) who also have at least two heart-related conditions. The goal is to see if the two-drug approach lea…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION (PAH)
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Malaria drug artesunate tested for rare lung condition
Disease control Recruiting nowThis early-stage study is testing whether artesunate, a drug used for malaria, is safe for people with pulmonary arterial hypertension (PAH). Fifteen adults with PAH will take increasing doses of artesunate capsules for 20 weeks. The main goal is to check for side effects, not ye…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION (PAH)
Phase: PHASE1 • Sponsor: Joseph C. Wu • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Simple coaching may boost inhaler use in rare lung disease
Disease control Recruiting nowThis study tests whether extra guidance from a pharmacist can help people with pulmonary arterial hypertension (PAH) use their inhaled iloprost correctly and consistently. PAH is a rare, serious lung condition that makes it hard to breathe. The trial will enroll 72 adults who alr…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION (PAH)
Phase: NA • Sponsor: University of Sao Paulo General Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug aims to unload the heart in lung hypertension
Disease control Recruiting nowThis study tests whether the drug sotatercept can improve right heart function in people with pulmonary arterial hypertension (PAH). PAH causes high blood pressure in the lungs, straining the right side of the heart. Sotatercept targets the underlying blood vessel changes, not ju…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION (PAH)
Phase: PHASE4 • Sponsor: Amsterdam UMC, location VUmc • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
PAH drug switch under the microscope: will patients benefit?
Knowledge-focused Recruiting nowThis study looks at what happens when people with pulmonary arterial hypertension (PAH) switch from one medication (ambrisentan) to another (bosentan). Researchers will track 121 adults to see if their risk level, symptoms, and side effects change after the switch. The goal is to…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION (PAH)
Sponsor: University of Sao Paulo General Hospital • Aim: Knowledge-focused
Last updated Jul 08, 2026 00:00 UTC
-
New quiz aims to boost lung disease care
Knowledge-focused Recruiting nowThis study is creating and testing a questionnaire called SAVOIR to measure how much people with pulmonary arterial hypertension (PAH) understand about their condition. Up to 215 patients and expert judges will help ensure the questions are clear, relevant, and reliable. The goal…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION (PAH)
Phase: NA • Sponsor: University of Sao Paulo General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Study aims to uncover why a deadly lung disease is often diagnosed too late
Knowledge-focused Recruiting nowThis study looks at how long it takes for people in Brazil to get a correct diagnosis of pulmonary arterial hypertension (PAH), a rare and serious lung disease. Researchers will review medical records of about 139 adults diagnosed in the last five years to find out what causes de…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION (PAH)
Sponsor: University of Sao Paulo General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC